Back to results
US 7,256,015 B2Granted
TALL-1 receptor molecules and uses thereof
AssigneeAmgen Inc.
InventorHailing Hsu
Life of this patent
Estimating the term…
Abstract
The present invention provides tumor necrosis factor and apoptosis ligand-related leukocyte-expressed ligand 1 receptor (TALL-1R) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TALL-1R polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with TALL-1R polypeptides.
Claims20
An isolated nucleic acid molecule comprising:
- (a) the nucleotide sequence as set forth in any of SEQ ID NO:
- 1, SEQ ID NO:
- 3, or SEQ ID NO:
- 5;
- (b) a nucleotide sequence encoding the polypeptide as set forth in any of SEQ ID NO:
- 2, SEQ ID NO:
- 4, SEQ ID NO:
- 6, SEQ ID NO:
- 7, or SEQ ID NO:
- 14;
- (c) a nucleotide sequence that hybridizes to the complement of the nucleotide sequence of either (a) or (b) at 50° C. in a hybridization buffer comprising 0.015 M sodium chloride and 0.0015 M sodium citrate;
- or
- (d) a nucleotide sequence that is complementary to the nucleotide sequence of any of (a)-(c).
10 more elements
An isolated nucleic acid molecule comprising:
- (a) a region of the nucleotide sequence of any of SEQ ID NO:
- 1, SEQ ID NO:
- 3, or SEQ ID NO:
- 5 encoding a polypeptide of at least 25 amino acid residues;
- (b) a region of the nucleotide sequence of any of SEQ ID NO:
- 1, SEQ ID NO:
- 3, or SEQ ID NO:
- 5 comprising at least 16 nucleotides;
- (c) a nucleotide sequence that hybridizes to the complement of the nucleotide sequence of either (a) or (b) at 50° C. in a hybridization buffer comprising 0.015 M sodium chloride and 0.0015 M sodium citrate;
- or
- (d) a nucleotide sequence that is complementary to the nucleotide sequence of any of (a)-(c).
8 more elements
An isolated nucleic acid molecule comprising:
- (a) a nucleotide sequence encoding a polypeptide as set forth in any of SEQ ID NO:
- 2, SEQ ID NO:
- 4, SEQ ID NO:
- 6, SEQ ID NO:
- 7, or SEQ ID NO:
- 14 that has a C- and/or N-terminal truncation, wherein the encoded polypeptide is capable of specifically binding TALL-1;
- (b) a nucleotide sequence that hybridizes to the complement of the nucleotide sequence of at 50° C. in a hybridization buffer comprising 0.015 M sodium chloride and 0.0015 M sodium citrate;
- or
- (c) a nucleotide sequence that is complementary to the nucleotide sequence of either (a) or (b).
6 more elements
An isolated nucleic acid molecule comprising:
- (a) a region of the nucleotide sequence of any of SEQ ID NO:
- 1, SEQ ID NO:
- 3, or SEQ ID NO:
- 5, encoding a polypeptide comprising amino acid residues 1-40, 1-38, 11-38, or 17-38 of the amino acid sequence as set forth in any of SEQ ID NO:
- 2, SEQ ID NO:
- 4, SEQ ID NO:
- 6, or SEQ ID NO:
- 7;
- (b) a region of the nucleotide sequence of either SEQ ID NO:
- 1 or SEQ ID NO:
- 3, encoding a polypeptide comprising amino acid residues 1-84 of the amino acid sequence as set forth in any of SEQ ID NO:
- 2, SEQ ID NO:
- 4, or SEQ ID NO:
- 7;
- or
- (c) a region of the nucleotide sequence of SEQ ID NO:
- 5, encoding a polypeptide comprising amino acid residues 1-83 of the amino acid sequence as set forth in SEQ ID NO:
- 6.
15 more elements
A process of producing a polypeptide encoded by a nucleic acid molecule having:
- (a) the nucleotide sequence as set forth in any of SEQ ID NO:
- 1, SEQ ID NO:
- 3, or SEQ ID NO:
- 5;
- (b) a region of the nucleotide sequence of any of SEQ ID NO:
- 1, SEQ ID NO:
- 3, or SEQ ID NO:
- 5 encoding a polypeptide of at least 25 amino acid residues;
- (c) a nucleotide sequence encoding a polypeptide as set forth in any of SEQ ID NO:
- 2, SEQ ID NO:
- 4, SEQ ID NO:
- 6, SEQ ID NO:
- 7, or SEQ ID NO:
- 14 that has a C- and/or N-terminal truncation, wherein the encoded polypeptide is capable of specifically binding TALL-1;
- (d) a region of the nucleotide sequence of any of SEQ ID NO:
- 1, SEQ ID NO:
- 3, or SEQ ID NO:
- 5, encoding a polypeptide comprising amino acid residues 1-40, 1-38, 11-38, or 17-38 of the amino acid sequence as set forth in any of SEQ ID NO:
- 2, SEQ ID NO:
- 4, SEQ ID NO:
- 6, or SEQ ID NO:
- 7;
- (e) a region of the nucleotide sequence of either SEQ ID NO:
- 1 or SEQ ID NO:
- 3, encoding a polypeptide comprising amino acid residues 1-84 of the amino acid sequence as set forth in any of SEQ ID NO:
- 2, SEQ ID NO:
- 4, or SEQ ID NO:
- 7;
- (f) a region of the nucleotide sequence of SEQ ID NO:
- 5, encoding a polypeptide comprising amino acid residues 1-83 of the amino acid sequence as set forth in SEQ ID NO:
- 6;
- (g) a nucleotide sequence that is a degenerate variant of the nucleotide sequence of any of (a), (b), (d), (e), or (f);
- or
- (h) a nucleotide sequence that hybridizes to the complement of the nucleotide sequence of any of (a)-(f) at 65° C. in a hybridization buffer comprising 0.015 M sodium chloride and 0.0015 M sodium citrate;
- comprising culturing a host cell containing the nucleic acid molecule under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.
32 more elements
A fusion polypeptide comprising a first polypeptide and a second polypeptide, wherein the first polypeptide is encoded by a nucleic acid molecule having:
- (a) the nucleotide sequence as set forth in any of SEQ ID NO:
- 1, SEQ ID NO:
- 3, or SEQ ID NO:
- 5;
- (b) a region of the nucleotide sequence of any of SEQ ID NO:
- 1, SEQ ID NO:
- 3, or SEQ ID NO:
- 5 encoding a polypeptide of at least 25 amino acid residues;
- (c) a nucleotide sequence encoding a polypeptide as set forth in any of SEQ ID NO:
- 2, SEQ ID NO:
- 4, SEQ ID NO:
- 6, SEQ ID NO:
- 7, or SEQ ID NO:
- 14 that has a C- and/or N-terminal truncation, wherein the encoded polypeptide is capable of specifically binding TALL-1;
- (d) a region of the nucleotide sequence of any of SEQ ID NO:
- 1, SEQ ID NO:
- 3, or SEQ ID NO:
- 5, encoding a polypeptide comprising amino acid residues 1-40, 1-38, 11-38, or 17-38 of the amino acid sequence as set forth in any of SEQ ID NO:
- 2, SEQ ID NO:
- 4, SEQ ID NO:
- 6, or SEQ ID NO:
- 7;
- (e) a region of the nucleotide sequence of either SEQ ID NO:
- 1 or SEQ ID NO:
- 3, encoding a polypeptide comprising amino acid residues 1-84 of the amino acid sequence as set forth in any of SEQ ID NO:
- 2, SEQ ID NO:
- 4, or SEQ ID NO:
- 7;
- (f) a region of the nuclcotidc sequence of SEQ ID NO:
- 5, encoding a polypeptide comprising amino acid residues 1-83 of the amino acid sequence as set forth in SEQ ID NO:
- 6;
- (g) a nucleotide sequence that is a degenerate variant of the nucleotide sequence of any of (a), (b), (d), (e), or (f);
- or
- (h) a nucleotide sequence that hybridizes to the complement of thc nucleotide sequence of any of (a)-(f) at 65° C. in a hybridization buffer comprising 0.015 M sodium chloride and 0.0015 M sodium citrate;
- and the second polypeptide has an amino acid sequence that is heterologous to the first polypeptide.
32 more elements
Dependencies are inferred from the claim text.